feed,title,long_url,short_url
Benzinga,Proof of Concept Controlled Phase 2 Clinical Trial Data Evaluating ANAVEXÂ®2-73 (blarcamesine) in Parkinson's Disease Dementia Presented at CTAD 2020 Conference,https://www.benzinga.com/pressreleases/20/11/g18250729/proof-of-concept-controlled-phase-2-clinical-trial-data-evaluating-anavex-2-73-blarcamesine-in-par,https://j.mp/2GFtin6
